1-2 of 2
Tetsuya Mori, MD,PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Trial of CH5424802 (alectinib hydrochloride) for Recurrent or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

Masahiro Sekimizu, MD PhD, Reiji Fukano, MD PhD, Ilseung Choi, MD PhD, Akiko Kada, PhD, Akiko Saito, MD, Ryuta Asada, PhD, Tetsuya Mori, MD PhD, Hirokazu Nagai, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2924.
https://doi.org/10.1182/blood-2018-99-112708
Published: 2018
Journal Articles

Outcome of 136 Children with Advanced Lymphoblastic Lymphoma Receiving an BFM-Type Therapy with Intensified Maintenance: A Report from the Japanese Pediatric Leukemia/Lymphoma Study Group ALB-NHL03 Study

Shosuke Sunami, MD, PhD, Masahiro Sekimizu, MDPhD, Tetsuya Takimoto, MD,PhD, Tetsuya Mori, MD,PhD, Tetsuo Mitsui, MD, PhD, Reiji Fukano, MD, PhD, Takeshi Mori, MD, PhD, Atsushi Kikuta, MD PhD, Koh Katsuyoshi, MD,PhD, Toshihiko Imamura, MD, PhD, Akiko Moriya Saito, MD, PhD, Tomoyuki Watanabe, PhD, Kouichi Ohshima, MD, PhD, Junichiro Fujimoto, MD, PhD, Atsuko Nakazawa, MD, PhD, Ryoji Kobayashi, MD, PhD, Keizo Horibe, MD, Masahito Tsurusawa, MD, PhD
Journal: Blood
Blood (2014) 124 (21): 3049.
https://doi.org/10.1182/blood.V124.21.3049.3049
Published: 2014